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Objective: The microfracture technique activates mesenchymal progenitors that enter the cartilage defect
and form cartilage repair tissue. Synovial ﬂuid (SF) has been shown to stimulate the migration of sub-
chondral progenitors. The aim of our study was to determine the chemokine proﬁle of SF from normal,
rheumatoid arthritis (RA) and osteoarthritis (OA) donors and evaluate the chemotactic effect of selected
chemokines on human subchondral progenitor cells.
Method: Chemokine levels of SF were analyzed using human chemokine antibody membrane arrays. The
chemotactic potential of selected chemokines on human mesenchymal progenitors derived from sub-
chondral cortico-spongious bone was tested using 96-well chemotaxis assays. Chemokine receptor
expression of subchondral progenitors was assessed by real-time gene expression analysis and immuno-
histochemistry.
Results: Chemokine antibody array analysis showed that SF contains a broad range of chemokines. Ten
chemokines that showed signiﬁcantly reduced levels in RA or OA compared to normal SF or robustly high
levels in all SF tested were used for further chemotactic analysis. Chemotaxis assays showed that the
chemokines MDC/CCL22, CTACK/CCL27, ENA78/CXCL5 and SDF1a/CXCL12 signiﬁcantly inhibited migra-
tion of progenitors, while TECK/CCL25, IP10/CXCL10 and Lymphotactin/XCL1 effectively stimulated cell
migration. MCP1/CCL2, Eotaxin2/CCL24 and NAP2/CXCL7 showed no chemotactic effect on subchondral
progenitors. Gene expression and immuno-histochemical analysis of corresponding chemokine receptors
document presence of low levels of chemokine receptors in subchondral progenitors, with the CXCL10
receptor CXCR3 showing the highest expression level.
Conclusion: These results suggest that SF contains chemokines that may contribute to the recruitment of
human mesenchymal progenitors from the subchondral bone in microfracture.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Bonemarrowstimulating techniques likedrillingormicrofracture
are frequently used ﬁrst-line treatment options for cartilage lesions.
These techniques provide access to the subchondral bone marrow: Christian Kaps, TransTissue
n, Germany. Tel: 49-30-450-
. Kaps).
s Research Society International. Pand allowmesenchymal progenitor cells from themarrow tomigrate
into and populate the defect. Subsequently, progenitors form a non-
hyaline cartilaginous repair tissue1e6. The cellular mechanisms that
underlie recruitment of progenitors to the defective site and guiding
of the progenitors towards repair tissue formation are scarcely
understood. Mesenchymal progenitors from the subchondral bone
marrow may enter the defect passively by the blood ﬂow and form
cartilaginous repair tissue upon stimulation with angiogenic factors,
growth and differentiation factors as well as cytokines that are
released from the subchondral bone4,7. Recently, it has been shown
that synovial ﬂuid (SF) may also induce cartilage tissue formation by
mesenchymal progenitors as shown by chondrogenic differentiationublished by Elsevier Ltd. All rights reserved.
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ﬁbrocytes treatedwith SF8,9. In a previous study, we have shown that
SF recruit subchondral mesenchymal progenitor cells and therefore
may contribute to the population of the defective site by progenitors
in microfracture. These multi-potent progenitor cells derived from
the subchondral spongious bone, called cortico-spongious progeni-
tors (CSP), have beenshowntomigrate upon stimulationwithhuman
SF, with normal and osteoarthritis (OA) SF showing an elevated
recruiting potential compared to SF obtained from rheumatoid
arthritis (RA) donors10. Obviously, SF may play an important role in
progenitor cell recruitment and differentiation in microfracture and,
in addition, provides the articular environment with hyaluronan,
growth factors, inﬂammatory cytokines as well as chemokines,
depending on the inﬂammatory, normal or degenerative condition of
the joint11e14.
Chemokines are chemotactic cytokines and comprise a family of
more than 50 members that are structurally related to one of the
four subgroups of C, CC, CXC, and the CX3C chemokines and signal
through binding of G protein coupled seven transmembrane-
spanning serpentine receptors15,16. In addition to their immuno-
logical function in inﬂammation and homing, the pattern of
chemokines and chemokine receptors in normal and OA chon-
drocytes as well as inmesenchymal stem cells (MSC) differentiating
towards the chondrocyte phenotype suggests that chemokines
have an impact in cartilage homeostasis and release of matrix-
degrading enzymes in normal cartilage remodeling as well as in
cartilage destruction17,18,19. In recent years, human MSC have been
shown to express a broad range of chemokine receptors and
a variety of chemokines have been reported to stimulate the
migration of MSC obtained from bone marrow aspirates20e23.
However, the role of chemokines or chemo-attractants in mesen-
chymal progenitor migration from the subchondral bone marrow
to sites of cartilage defects in microfracture is unclear.
In this study, we analyzed the chemokine proﬁle of SF derived
from normal, OA and RA donors that have been shown previously to
recruit human subchondral progenitor cells10. High level chemo-
kines and chemokines with reduced levels in RA and OA SF
compared to normal SF were tested for the recruitment of human
mesenchymal progenitor cells derived from the subchondral spon-
gious bone. Progenitors showed a distinct set of chemokine recep-
tors and were recruited by the chemokines CCL25, CXCL10 and XCL1,
while the chemokines CCL22, CCL27, CXCL5 and CXCL12 had an
inhibitory and CCL2, CCL24 and CXCL7 had no effect on progenitor
cell migration. Therefore, it is suggested that chemokines of the SF
may be involved in the migration of multi-potent progenitors from
the subchondral bone marrow to the defective site in microfracture.
Method
Isolation and cultivation of human cortico-spongious
progenitor cells
Human subchondral progenitor cells CSP were isolated from
subchondral cortico-spongious bone containing marrow
(one female, threemales, age 40e68 years) from the lateral tibia head
during high tibial closed wedge osteotomy as described previously.
CSP have a multi-potential differentiation capacity and are routinely
tested for typical stem cell-like cell-surface antigen pattern with
presence of SH2, CD73, CD90, and CD166 as well as absence of CD3,
CD14, CD34, and CD4524.
In brief, spongious bonewas cut into small fragments, digested for
4 h at 37C using 256 U/ml collagenase XI (Sigma) and placed in cell
culture ﬂasks (Becton Dickinson) with DME-medium (Biochrom)
containing 10% human serum (German Red Cross), 100 U/ml peni-
cillin, 100 mg/ml streptomycin, 2 mM L-glutamine (all Biochrom) and2 ng/mlﬁbroblast growth factor-2 (Tebu-bio). At 80e90% conﬂuence,
CSPwere harvested using trypsineEDTA in PBS (0.05%v/v, Biochrom)
and re-plated at a density of 6,000 cells/cm2.Mediumwas exchanged
every 2e3 days. The study was approved by the ethics committee of
the Charité-Universitätsmedizin Berlin.
Collection of SF
SF used in the current study has already been shown to recruit
humanCSP in a previous study10. In brief, RA SFwas obtained by joint
puncture (ﬁve females;mean age 45.4 years;meanDAS 28 6.6;mean
ESR (1 h) 74.2; mean CrP 6.96 mg/dl) from patients diagnosed
according to the revised American College of Rheumatology criteria
for the Classiﬁcation of RA25. One donor with RA received disease
modifying anti-rheumatic drugs (DMARD). Two donors had DMARD
and steroidal anti-inﬂammatory drugs (SAID), one donor received
SAID and non-steroidal anti-inﬂammatory drugs (NSAID), and one
donor had only NSAID. None of the patients received intra-articular
therapy. OA SF was obtained by joint puncture (ﬁve females; mean
age 62.0 years;mean ESR (1 h) 12;mean CrP 0.7 mg/dl) frompatients
diagnosed according to the American College of Rheumatology
criteria for the classiﬁcation and reporting of OA26. Three of the
donorswithOA receivedNSAID and twodonors hadnomedication at
the time of joint puncture. ND SF was obtained post mortem from
organ donors (three females, two males; mean age 53.2 years)
without joint diseases. All procedures were performed in consent
with the ethics committee of the Charité-Universitätsmedizin Berlin.
Human chemokine antibody membrane array analysis
The levels of 38 chemokineswere analyzed in individual samples
of SF derived from ND (n¼ 5), OA (n ¼ 5) and RA (n¼ 5) using
human chemokine antibody membrane arrays (RayBiotech)
according to themanufacturer’s recommendations (n¼ 15 arrays in
total). The conﬁguration of the chemokine antibody membrane
array is given in Fig. 1(D). For normalization, the protein content of
SF was measured using the BCA (bicinchoninic acid) assay (Sigma).
After blocking, membranes were incubated for 2 h with 0.6 mg/ml
SFat 20C. Detection of chemokineswas performed according to the
manufacturer’s recommendations by biotin-conjugated antibodies
raised against the particular chemokines and horseradish peroxi-
dase-conjugated streptavidin. For detection by chemiluminescence,
themembranes were brieﬂy exposed to X-ray ﬁlms (Amersham) for
1.0 min. Images were digitized at a resolution of 300 d.p.i. and spot
intensity was determined by densitometric measurement. In brief,
a color was deﬁned representing the background color of the array
in a given area (negative control). For each spot, the number of
stained and unstained pixels was determined within a given area.
For normalization of arrays, signal values of chemokines were
divided by the mean value of the positive control and multiplied
with 100. A value of 100 represents a spot intensity as shown in the
positive control, while a value of zero represents the spot intensity
as seen in the negative control.
Analysis of chemokine mediated chemotaxis
Chemotactic activity of the chemokines (all PeproTech) CXCL5
(ENA78), CXCL7 (NAP2), CXCL10 (IP10), CXCL12 (SDF1a), CCL2
(MCP1), CCL22 (MDC), CCL24 (Eotaxin2), CCL25 (TECK), CCL27
(CTACK), and XCL1 (Lymphotactin) was measured in 96-well
chemotaxis assays with 8 mm polycarbonate membranes (Neurop-
robe), in triplicates using three independent CSP preparations each
(n¼ 9 assays per chemokine and dose). Brieﬂy, 3104 CSP (passage
three) were re-suspended in DME-medium containing 0.1% FBS and
seeded in the upper wells. In the lower wells, 0 nMe1,000 nM of
Fig. 1. Chemokine proﬁle of human SF. Representative chemokine antibody array membranes showing the chemokine proﬁle of SF derived from normal (A), OA (B) and RA
(C) donors. The respective chemokines were measured in duplicates per array (D). In total, per group n¼ 5 SF were analyzed. Note that levels of a given chemokine can be compared
from array to array, but not the levels of one chemokine to the other. Positive controls on the array membrane are streptavidin conjugated horseradish peroxidase and negative
controls are bovine serum albumins.
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given. Chemokinesis was excluded by testing cell migration with
50 nM or 1,000 nM of the chemokine in DME-medium containing
0.1% FBS, added to the upper and lower wells. The chambers were
incubated for 20 h at 37C. After removal of non-responding cells
on top of the ﬁlter, CSP that migrated through the membrane were
ﬁxed in methanol/acetone, stained with Hemacolor (Merck) and
enumerated microscopically by counting the number of stained
cells in three representative ﬁelds. Data were normalized by
calculating the ‘migration index’ (ratio between migrated CSP upon
chemokine treatment and migrated CSP in the absence of the
chemokine) and statistical analysis was performed.
Immuno-histochemistry
Staining of chemokine receptors was performed in duplicates.
CSP (passage three) were seeded in chamber-slides at a density of
5,000 cells/cm2 and cultured for 24 h in the presence of 10% human
serum from whole blood. Cells were ﬁxed with ice-cold methanol/
acetone (1:1 v/v) and incubated with the primary mouse anti-
human CXCR3 (RD Systems), mouse anti-human CCR9 (RD Systems),
or rabbit anti-human XCR1 (Acris Antibodies) for 40min. Rabbit or
mouse IgG (DAKO) served as controls. Subsequently, cells were
processed using the EnVision System Peroxidase Kit (DAKO)
according to the manufacturer’s instructions, followed by counter-
staining with hematoxylin (Merck).
Polymerase chain reaction (PCR)
Total RNA from CSP (n¼ 3 donors, passage three) was isolated as
described27 and RNA (5 mg) was reversely transcribed with the
iScript cDNA Synthesis Kit according to the manufacturer’s instruc-
tions (BioRad). The relative expression level of the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
to normalize samples. Real-time PCR using the i-Cycler PCR System
(BioRad) was performed with 1 ml of cDNA sample using the SYBRGreen PCR Core Kit (Applied Biosystems) in triplicates per donor
(n¼ 9 assays in total). Relative quantitation of chemokine receptor
expression (Table I) was performed and is given as percentage of the
GAPDH product.
Statistical analysis
For analysis of chemokine levels in SF, the KolmogoroveSmirnov
method was applied for testing normal distribution of the data. For
normal distributed data, the t-test was applied, while the Man-
neWhitney rank sum test was used for data that failed normality
testing. Differences were considered signiﬁcant at P< 0.05.
For statistical analysis of CSP recruitment upon chemokine
treatment, the KolmogoroveSmirnovmethodwas applied for testing
normal distribution of the data. Normal distributed recruitment data
were further analyzed with the one way repeated measures (RM)
analysis of variance (ANOVA) and data without normal distribution
with RM ANOVA on ranks. Subsequently, all pairwise multiple
comparison procedures (Student-NewmaneKeuls method (SNK) for
all pairwise comparisons and Dunnett’s method for comparison vs
control/0 nM) were applied and differences were considered signif-
icant at P< 0.05. For calculation of exact P-values, the parametric
paired t-test or the non-parametric Wilcoxon signed rank test was
applied. The 95% conﬁdence interval (CI) was calculated and the
lower and upper limit is given.
Results
Chemokine levels in normal, RA and OA SF
To analyze chemokines in SF fromnormal [Fig.1(A)], OA [Fig.1(B)]
and RA donors [Fig. 1(C)], human chemokine antibody arrays were
used. The array conﬁguration with all chemokines measured in
duplicates is given in Fig. 1(D). Densitometric analysis showed that
the chemokines CCL2, CCL24, CCL27 and CXCL5 are signiﬁcantly
reduced, while the chemokines CCL1, CCL7, CCL13 and CXCL1
Table II
Proﬁle of selected chemokines in SF derived from normal, OA and RA donors
Chemokine ND OA RA
Name Synonym Mean Range
Max/Min
Mean Range
Max/Min
Mean Range
Max/Min
CXCL7 NAP2 48.5 89.9/5.8 36.3 60.6/23.0 39.1 65.3/23.9
CCL22 MDC 38.2 50.4/22.7 29.9 43.4/21.3 28.8 31.0/24.7
CCL2 MCP1 26.4 48.0/14.7 12.1 28.5/1.1 9.9 14.4/5.9
CXCL5 ENA78 22.7 26.5/19.2 15.0 23.9/9.8 13.1 15.6/10.8
CXCL10 IP10 21.1 27.0/14.0 16.7 23.2/9.4 16.2 20.5/14.2
XCL1 Lymphotactin 20.4 29.1/16.7 15.5 22.2/5.1 15.5 20.1/13.2
CCL24 Eotaxin2 20.4 28.5/10.9 12.1 29.7/4.7 10.2 13.5/8.3
CCL27 CTACK 16.7 22.1/13.8 10.3 21.0/3.4 8.9 10.7/8.3
CXCL12 SDF1a 2.3 9.6/0.0 1.1 3.6/0.0 0.7 2.3/0.0
CCL25 TECK 1.8 5.7/0.2 3.6 9.5/0.0 2.3 4.9/0.1
Chemokine Ratio P-value
Name Synonym OA/ND RA/ND OA/RA OA/ND RA/ND OA/RA
CXCL7 NAP2 1.3 1.2 1.1 e e e
CCL22 MDC 1.3 1.3 1.0 e e e
CCL2 MCP1 2.2 2.7 1.2 e 0.0481 e
CXCL5 ENA78 1.5 1.7 1.1 0.0241 0.0002 e
CXCL10 IP10 1.3 1.3 1.0 e e e
XCL1 Lymphotactin 1.3 1.3 1.0 e e e
CCL24 Eotaxin2 1.7 2.0 1.2 e 0.0102 e
CCL27 CTACK 1.6 1.9 1.1 e 0.0079 e
CXCL12 SDF1a 2.1 3.3 1.6 e e e
CCL25 TECK 2.0 1.3 1.6 e e e
Table I
Oligonucleotides
gene
name
Reference
sequence
Oligonucleotides (50/30) (up/down) Product size
(Base pairs)
GAPDH* NM_002046 GGC GAT GCT GGC GCT GAG TAC/
TGG TCC ACA CCC ATG ACG A
149
CXCR1 NM_000634 CTG AGC CCC AAG TGG AAC GAG ACA/
GCA CGG AAC AGA AGC TTT ATT AGG A
152
CXCR2 NM_001557 CAA TGA ATG AAT GAA TGG CTA AG/
AAA GTT TTC AAG GTT CGT CCG TGT T
118
CXCR3 NM_001504 CCC GCA ACT GGT GCC GAG AAA G/
AGG CGC AAG AGC AGC ATC CAC AT
148
CXCR4 NM_003467 ATC CCT GCC CTC CTG CTG ACT ATT C/
GAG GGC CTT GCG CTT CTG GTG
231
CXCR7 NM_020311 GCT GCG TCA ACC CTG TCC TCT AC/
GGC CCA TCA CCC TGT TCA AAA A
224
CCR2 NM_000647 CTA CCT TCC AGT TCC TCA TTT TT/
ACA TTT ACA AGT TGC AGT TTT CAG C
100
CCR3 NM_178329 TTT GTC ATC ATG GCG GTG TTT TTC/
GGT TCA TGC AGC AGT GGG AGT AG
169
CCR4 NM_005508 GAG AAG AAG AAC AAG GCG GTG AAG A/
GGA TTA AGG CAG CAG TGA ACA AAA G
200
CCR9 NM_031200 TAT ACA GCC AAA TCA AGG AGG AAT C/
CAT GAC CAC GAA GGG AAG GAA G
137
CCR10 NM_016602 GGG CTG GAG TCT GGG AAG TGC/
ACG ATG ACG GAG ACC AAG TGT GC
183
XCR1 NM_005283 CAT CAT GAC CAT CCA CCG CTA CC/
TCG AGG ATG GAG GAC AGG ATG C
129
* Glyceraldehyde-3-phosphate dehydrogenase.
Table III
Migration index (migrated CSP/control) of selected chemokines that showed an
inhibitory effect on migration of subchondral progenitor cells
Migration index SNK P< 0.05
vs 0 nM
P-value*
vs 0 nM
nM N Mean CI (95%)
Lower
limit
CI (95%)
Upper
limit
CCL22
0 9 1.00 0.81 1.19 e e
1 9 1.22 0.61 1.84 No 0.4145
10 9 1.14 0.83 1.45 No 0.4170
50 9 0.91 0.70 1.13 No 0.4753
100 9 1.02 0.71 1.33 No 0.8720
250 9 1.03 0.84 1.22 No 0.7348
500 9 0.75 0.63 0.87 No 0.0240
1,000 9 0.61 0.42 0.80 No 0.0078
CCL27
0 9 1.00 0.87 1.13 e e
1 9 1.19 0.94 1.44 No 0.1731
10 9 1.32 1.02 1.62 No 0.0387
50 9 1.09 0.92 1.26 No 0.2855
100 9 0.81 0.69 0.93 No 0.0534
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was signiﬁcantly reduced compared to normal SF and the level of
CCL1 was decreased in OA SF compared to RA SF (Table I,
Supplementary material). The highest spot intensities were found
for the chemokines CXCL7 and CCL22 with 28e48% of the intensity
measured in positive control spots, while the lowest intensities were
found for CCL7 and CCL8, which were virtually absent in normal SF.
The complete chemokine proﬁle is given in Table II of the
Supplemental material.
Since a previous study showed that RA SF showed reduced
chemotactic activity on human subchondral progenitors compared
to normal and OA SF, the chemokines CCL2, CCL24, CCL27 and
CXCL5, which are signiﬁcantly reduced in RA SF, were selected for
further analysis in chemotaxis assays. In addition, representative
chemokines were selected that showed high (CXCL7, CCL22),
moderate (CXCL10, XCL1) or low (CXCL12, CCL25) intensities in
normal, OA and RA SF (Table II).250 9 0.54 0.43 0.65 No 0.0008
500 9 0.72 0.52 0.92 No 0.0343
1,000 9 1.32 0.93 1.71 No 0.1151
CXCL5
0 9 1.00 0.81 1.19 e e
1 9 0.99 0.71 1.27 No 0.9414
10 9 0.74 0.54 0.94 No 0.0605
50 9 0.80 0.62 0.98 No 0.1568
100 9 0.81 0.59 1.03 No 0.2220
250 9 0.55 0.39 0.71 Yes 0.0043
500 9 0.47 0.34 0.60 Yes 0.0001
1,000 9 0.62 0.32 0.92 Yes 0.0534
CXCL12
0 9 1.00 0.84 1.16 e e
1 9 0.81 0.65 0.97 No 0.1322
10 9 0.89 0.71 1.07 No 0.3535
50 9 0.73 0.58 0.88 Yes 0.0019
100 9 0.50 0.31 0.69 Yes 0.0014
250 9 0.64 0.51 0.77 Yes 0.0039
500 9 0.40 0.19 0.61 Yes 0.0006
1,000 9 1.04 0.74 1.35 No 0.7207
* Paired t-test/Wilcoxon signed rank test.Chemokine induced migration of human subchondral
progenitor cells
Stimulation of CSP with CCL2, CCL24 or CXCL7 showed no effect
on progenitor migration (data not shown). The chemokines CCL22,
CCL27, CXCL5 and CXCL12 did not recruit CSP but showed
a moderate inhibition of cell migration (Table III). In controls, in the
absence of CCL22, spontaneous migration occurred with a mean
migration index of 1.0 and a CI of 0.81e1.19. Stimulation with
1,000 nM of CCL22 reduced the mean migration index (CI ranging
from 0.42 to 0.80) compared to untreated controls. Compared to
untreated CSP, 250 nMe500 nM CCL27 showed an inhibitory effect
on the migration of cells. In addition, stimulation with 250 nM of
CCL27 signiﬁcantly reduced the migration index (mean 0.54)
compared to all other doses tested (mean index ranging from 0.72
to 1.32). Signiﬁcant inhibition of cell recruitment occurred in the
presence of 250 nM and 1,000 nM CXCL5 (mean migration index of
0.47e0.55) as well as after stimulation with 50e500 nM CXCL12
Table IVa
Migration index (migrated CSP/control) of selected chemokines that showed
stimulation of migration of subchondral progenitor cells
Migration index SNK P< 0.05
vs 0 nM
P-value*
vs 0 nM
nM N Mean CI (95%)
Lower
limit
CI (95%)
Upper
limit
CCL25
0 9 1.00 0.86 1.14 e e
1 9 1.40 1.20 1.60 No 0.0124
10 9 1.37 1.17 1.57 No 0.0148
50 9 1.13 1.04 1.22 No 0.1641
100 9 1.07 0.96 1.12 No 0.4470
250 9 1.01 0.63 1.39 No 0.9696
500 9 1.91 1.06 2.76 No 0.0378
1,000 9 3.23 2.12 4.35 Yes 0.0018
CXCL10
0 9 1.00 0.75 1.23 e e
1 9 1.75 1.33 2.17 Yes 0.0061
10 9 2.31 0.91 3.71 Yes 0.0273
50 9 1.62 0.97 2.27 Yes 0.0758
100 9 2.00 1.23 2.77 Yes 0.0039
250 9 2.57 1.20 3.94 Yes 0.0291
500 9 2.56 1.72 3.41 Yes 0.0034
1,000 9 3.96 2.18 5.74 Yes 0.0039
XCL1
0 9 1.00 0.87 1.13 e e
1 9 1.22 1.04 1.41 No 0.0511
10 9 1.47 1.23 1.71 Yes 0.0015
50 9 1.30 0.96 1.64 No 0.0882
100 9 1.24 0.89 1.59 No 0.1308
250 9 1.01 0.80 1.22 No 0.9242
500 9 0.68 0.52 0.84 No 0.0072
1,000 9 0.84 0.49 1.19 No 0.2746
* Paired t-test/Wilcoxon signed rank test.
Table IVb
Number of migrated cells upon treatment of subchondral progenitor cells with
selected chemokines
Number of migrated cells SNK P< 0.05
vs 0 nM
P-value*
vs 0 nM
nM N Mean CI (95%)
Lower
limit
CI (95%)
Upper
limit
CCL25
0 9 1,342 1,102 1,582 e e
1 9 1,911 1,468 2,355 No 0.0156
10 9 1,846 1,479 2,213 No 0.0109
50 9 1,524 1,287 1,761 No 0.1641
100 9 1,451 1,154 1,748 No 0.3622
250 9 1,277 916 1,638 No 0.7585
500 9 2,435 1,553 3,317 No 0.0308
1,000 9 4,161 2,950 5,372 Yes 0.0009
CXCL10
0 9 1,331 766 1,896 e e
1 9 2,155 1,299 3,011 Yes 0.0315
10 9 2,102 1,766 2,438 Yes 0.0243
50 9 1,843 1,156 2,530 No 0.0947
100 9 2,123 1,629 2,617 Yes 0.0008
250 9 2,444 1,953 2,935 Yes 0.0080
500 9 2,837 2,078 3,596 Yes 0.0007
1,000 9 4,277 3,316 5,238 Yes <0.0001
XCL1
0 9 1,907 1,240 2,574 e e
1 9 2,302 1,474 3,130 No 0.0492
10 9 2,726 1,727 3,726 Yes 0.0046
50 9 2,596 1,319 3,874 No 0.0913
100 9 2,537 1,283 3,791 No 0.1017
250 9 1,991 1,090 2,892 No 0.7080
500 9 1,327 692 1,962 No 0.0096
1,000 9 1,406 753 2,059 No 0.1339
* Paired t-test/Wilcoxon signed rank test.
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controls.
In contrast, the chemokines CCL25, CXCL10 and XCL1 signiﬁcantly
recruited human subchondral mesenchymal progenitors (Table IV).
CSP cells stimulated with 1,000 nM CCL25 or 1 nMe1,000 nM
CXCL10 as well as 10 nM XCL1 showed signiﬁcantly elevated
migration indices compared to CSP not treated with a chemokine
(Table IVa). Stimulation of CSPwith1,000 nMCCL25 (meanmigration
index of 3.23) or 1,000 nM CXCL10 (mean migration index of 3.96)
showed effective cell recruitment and signiﬁcantly increased CSP
migration compared to CSP stimulated with 0 nMe500 nM of the
chemokine. Compared to 0 nM, 1 nM and 50e1,000 nM XCL1, 10 nM
of XCL1 showed signiﬁcant cell recruitment with the highest
migration index (mean migration index of 1.47). The use of 500 nM
and 1,000 nM of XCL1 inhibited CSP migration compared to
untreated cells,while 500 nMXCL1 reduced thenumber ofmigrating
cells compared to all other doses tested.
Numbers of migrating CSP upon chemokine treatment are given
inTable IVb. Compared to controls (mean; 1,342 CSP), stimulation of
CSP with 1,000 nM CCL25 (mean; 4,161 CSP) signiﬁcantly increased
the number of migrating cells. In cell recruitment by CXCL10 and
signiﬁcantly elevated compared to controls, the highest numbers of
migrating CSP occurred in the presence of 500 nM (mean; 2,837
migrating CSP) and of 1,000 nM CXCL10 (mean; 4,277 migrating
CSP). In the presence of 10 nM XCL1 in mean 2,726 CSP migrated.Chemokine receptors in subchondral progenitors
To assess whether human subchondral progenitors have che-
mokine receptors for chemokines tested in this study, PCR analysis
was performed (Fig. 2). In general, CSP showed low levels of theparticular chemokine receptors. CSP showed low expression levels
of CXCR1-4 and CXCR7 (mean, 0.0004e0.2451% of the expression
level of GAPDH) as well as of CCR2-3 and CCR9-10
(mean, 0.009e0.141%). CCR4 was virtually not expressed. The XCL1
receptor XCR1 showed a mean expression level of 0.06% of the
expression level of GAPDH. For the CCL25 receptor CCR9, the mean
expression level was 0.03% of the level found for GAPDH, while the
CXCL10 receptor CXCR3 showed a level of 0.2451% of the expression
level of GAPDH.
Immuno-histochemical staining (Fig. 3) conﬁrmed the presence
of the CXCL10 receptor CXCR3, the CCL25 receptor CCR9 and
the XCL1 receptor XCR1. Controls that were incubated with IgG and
the detection system gave no signal and indicated speciﬁcity of the
antibody staining.Discussion
In this study, we showed that human SF derived from normal,
OA and RA donors contain different levels of distinct chemokines.
A candidate subset is presented that shows chemokines with
reduced levels in RA or OA compared to normal SF or robustly high
levels in all SF. The chemokines CCL22, CCL27, CXCL5 and CXCL12
inhibited the migration of human subchondral mesenchymal
progenitor cells in vitro, while CCL2, CCL24 and CXCL7 had no effect
on progenitor cell attraction. The candidate chemokines CCL25
(TECK), CXCL10 (IP10) and XCL1 (Lymphotactin) effectively
recruited human subchondral progenitors. This suggests that SF
contains chemokines that may contribute to the migratory effect of
SF on human subchondral progenitors in microfracture.
The microfracture technique induces the formation of a carti-
laginous repair tissue by introducing multiple perforations into the
subchondral bone that allow for accessing the bone marrow and
Fig. 2. Gene expression analysis of human progenitor cells for selected chemokine
receptors. Real-time PCR analysis (n¼ 9) of three independent CSP preparations
(passage three) showed a low level of expression of CXCR1-4 and CXCR7 as well as
CCR2, CCR3, CCR9, CCR10 and XCR1. CCR4 was not detected. The mean of each
expression level is plotted and the error bars represent 95% CI (lower/upper limit).
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populate the defect and form the cartilage repair tissue28. The
mechanisms that underlie the migration of subchondral progenitor
cells from the marrow into the defect as well as their subsequent
differentiation towards chondrocytic cells still remain sparsely
understood. Migration and differentiation of the progenitors may
occur passively or may be actively triggered and inﬂuenced by
factors from the bone or the SF. Particular growth and differentia-
tion factors as well as cytokines enter the defect with the blood
ﬂow or may be released by the subchondral bone. These factorsFig. 3. Immuno-histochemical staining of chemokine receptors on human progenitor cells
respective receptors on human subchondral progenitor cells on the protein level. Controlsmay be involved in the recruitment and subsequent chondrogenic
differentiation of mesenchymal progenitors4,7. Recently, we have
shown that mesenchymal progenitor cells from the subchondral
bone have a high chondrogenic potential and that the chondrogenic
developmental process may be negatively inﬂuenced by inﬂam-
matory SF conditions found in RA24,29. In addition, SF actively
recruits mesenchymal progenitor cells from bone marrow10 or
potentially from the synovial tissue30. As shown here, the candidate
chemokines CCL25, CXCL10 and XCL1 that were deduced from the
different chemokine compositions of SF from normal, OA and RA
donors signiﬁcantly recruit human subchondral mesenchymal
progenitors, while others have no or an inhibitory effect on cell
migration. In MSC derived from, for instance, iliac crest bone
marrow aspirates, the chemokines CXCL5, CXCL7, CXCL10, CCL22,
and CCL25 have been shown to induce cell migration31e35. The
migratory effect of CXCL12 onMSC is discussed controversially with
studies showing CXCL12 mediated migration of MSC, while others
found no effect21e23. In contrast, the chemokines CCL2, CCL24,
CCL27 and XCL1 are known for not recruiting human MSC23,31,36.
The variable effects of chemokines on mesenchymal cells may due
to the restricted and partly different set of chemokine receptors
found in cells of different types or origin as known from stem cells
derived from iliac crest, periosteal cells or stem cells from osteo-
arthritic femoral heads23,37,38. Although mesenchymal progenitors
derived from the subchondral bone marrow share a variety of
characteristics with MSC derived from bone marrow aspirates, like
the cell-surface antigen pattern and the high chondrogenic differ-
entiation capacity24, there are obviously differences in the potential
to migrate and/or in the subset of chemokines that stimulate
migration of the progenitors. As shown here, subchondral mesen-
chymal progenitors do express chemokine receptors, are recruited
by a subset of chemokines that is present in human SF and therefore
chemokines may play an important role in the migration of sub-
chondral stem cells in microfracture treatment. However, further
studies have to elucidate which particular chemokine may mediate
migration of mesenchymal progenitors in vivo and/or in. Immuno-histochemical staining of CXCR3, CCR9 and XCR1 showed presence of the
gave no signal and show speciﬁcity of the antibody staining.
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not clear whether the chemokines detected in the SF are biologi-
cally active or inactive due to degradation or partial degradation.
The analysis of chemotactic events does not take into account that
growth factors from blood and from the subchondral bone as well
as from the synovial tissue may inﬂuence themigration potential of
mesenchymal progenitors in microfracture. In addition, in the joint,
potential chemotactic chemokines are present in mixture with
other chemokines as well as with growth factors and proteinases.
Therefore, to resemble the natural situation more closely, further
studies are needed that analyze potential synergistic or antago-
nistic effects of chemokine mixtures on stem cell migration in
microfracture. As shown here in subchondral CSP cells and in line
with previous studies with human MSC and periosteal cells23,35,38,
the doses of chemokines that stimulated or inhibited cell migration
were high and not physiological. Stem cells, periosteal cells and CSP
cells express a variety of chemokine receptors at a low level, this
may explain the high doses of chemokines needed for effective CSP
recruitment or inhibition of migration. In addition, the protein
content of SF was normalized prior to measurement of the che-
mokine levels, with higher protein content in RA and OA compared
to ND. Interestingly, chemokine levels found in RA and/or OA were
partly reduced compared to ND. This is in contrast to a variety of
studies that show that chemokines increase in the diseased
condition14. However, in general, in these studies the protein
content was not normalized. Although highly speculative, this may
indicate that in the diseased condition, (1) the protein content and
chemokinesmay increase in general due to invasion of cells into the
synovial lining layer and into the SF and (2) particular chemokines
may be disease-speciﬁcally induced in distinct cell type like
monocytes or T-cells. Clearly, further studies are needed that may
elucidate the general or disease-speciﬁc increase in joint diseases.
Although the synovial samples used in this study may be epide-
miologically representative for the diseased joint conditions,
a limitation of the study is that the samples derived from the
normal, RA and OA donors are in-homogenous with respect to
gender, age and potentially age-related hormonal changes in the
menopause as well as their disease-speciﬁc treatment regimen.
However, correlation of the obtained proﬁles to a particular treat-
ment, disease activity/severity or age was not evident. Since the
number of samples used in this study is limited, further studies are
needed that address the impact of age, hormones and medicinal
drugs on the proﬁle of chemokines in SF.
From the clinical point of view, the inﬂuence of SF or components
of the ﬂuid like chemokines on cartilage repair by microfracture
remains unclear and further studies are needed. Since the micro-
fracture technique often results in a hyaline to ﬁbrous cartilage repair
tissue with a limited short-term durability, approaches are deman-
ded that may enhance the content of matrix components and
improve cartilaginous repair tissue formation in microfracture5. In
addition, enhancement of stem cellmigration into and enrichment of
multi-potent progenitors within the defect, which subsequently
differentiate along the chondrogenic lineage and form the repair
tissue, may be also a promising approach for the improvement of
cartilage repair in microfracture. Recently, it has been shown that
MSC from bleeding microfractures enter a collagen membrane used
for covering of the defect39 and covering of microfractured defects
with a collagenmatrix,ﬁbrin glue and autologous serum is suggested
to be a promising treatment option for cartilage defects40. In a rabbit
model, cartilage repair has been shown by mesenchymal progenitor
cells from bone marrow that were attracted by a serum containing
blood clot in combination with a chitosan scaffold41,42. In addition,
the beneﬁt of covering microfractured cartilage defects has been
proven recently in the ovine model. Compared to conventional
microfracture treatment, the covering of microfractured defects witha resorbable scaffold made of polyglycolic acid and hyaluronan that
was immersed inautologous serum for cell recruitment improved the
formation of cartilage repair tissue that was rich in type II
collagen43,44. The ﬁrst clinical applications of the polyglycolic acid/
hyaluronan scaffold ﬁxed with resorbable pins in traumatic and
degenerated cartilage defects showed excellent defect ﬁlling as
assessed by magnet resonance imaging after 1 year follow-up45.
Although highly speculative, particular chemokines like CCL25,
CXCL10 and XCL1 as well as/or additional components of the SF like
lysophosphatic acid46 may have an impact in the population of
cartilage defects by multi-potent progenitors and may therefore
candidates for the improvement of the microfracture technique.
However, further studies are needed to clarify the role of chemokines
in stem cell migration and their possible use for improving cartilage
repair techniques like microfracturing.
Finally, our report shows the chemokine proﬁle of normal and
arthritic human SF and suggests that a subset of these chemokines
may contribute to the recruitment of human mesenchymal
progenitors from the subchondral bone.
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